<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822612</url>
  </required_header>
  <id_info>
    <org_study_id>15/LO/1756</org_study_id>
    <nct_id>NCT02822612</nct_id>
  </id_info>
  <brief_title>The EASE Study - Human Factor and Usability Testing of a Binocular OCT System</brief_title>
  <acronym>EASE</acronym>
  <official_title>A Prospective Single-Site Non-Interventional Study to Evaluate Human Factors and Usability of Automated, Comprehensive Ocular Examination in Elderly and Visually Impaired Populations Using a Prototype Binocular Optical Coherence Tomography System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University College, London</source>
  <brief_summary>
    <textblock>
      Ophthalmology is among the most technology driven of all medical specialties, with advanced
      medical imaging devices - and specialised computer software - increasingly adopted for
      routine clinical use. While many such devices are capable of completing specific tasks, lack
      of &quot;usability&quot; prevents their widespread adoption (i.e., such devices are not easy to learn
      and remember, or are not efficient or subjectively pleasing to use). Moreover, devices that
      are difficult to use expose patients to clinical risk as a result of human error during
      usage.

      With the introduction of a new medical technology, it is essential, therefore, to have a deep
      understanding of patients, what they need, what they value, their abilities, and also their
      limitations.

      Human factor and usability testing, also known as &quot;human factor engineering&quot;, deals with the
      formal study of people's interaction with their environment (in this case, the binocular
      optical coherence tomography (OCT) device). Structured, patient-centred, usability testing is
      essential to the design, clinical validation, regulatory approval, and widespread
      implementation, of all new medical devices. This is particularly the case for a putative
      binocular OCT system - a device intended for automated use in visually impaired, often
      elderly, populations. Although the binocular OCT is already at an advanced stage of hardware
      development, the EASE study will facilitate an iterative process of operating software and
      workflow modifications to optimize the device for use in these populations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Examination Time</measure>
    <time_frame>6 months</time_frame>
    <description>Total time for each participant to complete the binocular optical coherence tomography (OCT) examination was calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Subjective Ratings â‰¥ 4 on Post-Test Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Participants rated ease of use, duration, and appeal on a 5-point Likert scale in a post-test questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Presented Gradable Data, by Examination Type</measure>
    <time_frame>4 months</time_frame>
    <description>To identify potential user errors, particularly those with a likelihood of generating erroneous examination findings (e.g., failure to comply with device instructions or errors in voice recognition).</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">60</enrollment>
  <condition>Glaucoma</condition>
  <condition>Retinal Disease</condition>
  <condition>Strabismus</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Retinal Disease</arm_group_label>
    <description>Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma</arm_group_label>
    <description>Fifteen subjects with glaucoma. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Strabismus</arm_group_label>
    <description>Fifteen subjects with strabismus. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Fifteen healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Binocular OCT prototype</intervention_name>
    <description>Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).</description>
    <arm_group_label>Glaucoma</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Retinal Disease</arm_group_label>
    <arm_group_label>Strabismus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with chronic eye disease (retinal disease, glaucoma, and strabismus) will be
        recruited from appropriate eye clinics at Moorfields Eye Hospital and from a patient
        advisory group established for this purpose.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria for participants with chronic eye disease will include:

          -  Presence of retinal disease, glaucoma or strabismus

          -  Male or female, aged 18 years or older

          -  Ability to understand nature/purpose of the study and to provide informed consent

          -  Ability to undergo binocular OCT imaging

          -  Ability to follow instructions and complete the study

          -  Ability to speak English

        Exclusion criteria for participants with chronic eye disease will include:

          -  Optical media opacity sufficient to preclude adequate ocular imaging with OCT

          -  Hearing impairment sufficient to interfere with hearing instructions

          -  Any condition which, in the investigator's opinion, would conflict or otherwise
             prevent the subject from complying with the required procedures, schedule, or other
             study conduct.

        Inclusion criteria for healthy subjects will include:

          -  No self-reported ocular history (although wearing corrective prescription glasses is
             permitted)

          -  Male or female, aged 18 years or older

          -  Ability to understand nature/purpose of the study and to provide informed consent

          -  Ability to undergo binocular OCT imaging

          -  Ability to follow instructions and complete the study

          -  Ability to speak English

        Exclusion criteria for healthy subjects will include:

          -  Presence of ocular pathology

          -  Hearing impairment sufficient to interfere with hearing instructions

          -  Any condition which, in the investigator's opinion, would conflict or otherwise
             prevent the subject from complying with the required procedures, schedule, or other
             study conduct.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS FT</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <results_first_submitted>September 5, 2017</results_first_submitted>
  <results_first_submitted_qc>March 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2020</results_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>optical coherence tomography</keyword>
  <keyword>optical imaging</keyword>
  <keyword>retinal imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Retinal Disease</title>
          <description>Fourteen participants had bilateral retinal disease only (including 8 with age-related macular degeneration [AMD], 4 with diabetic macular edema, 1 with central serous retinopathy, and 1 with retinal vein occlusion with cystoid macular edema).</description>
        </group>
        <group group_id="P2">
          <title>Glaucoma</title>
          <description>Thirteen participants had glaucoma only (12 with primary open angle glaucoma [POAG], 1 with glaucoma secondary to hypertensive uveitis).</description>
        </group>
        <group group_id="P3">
          <title>Strabismus</title>
          <description>Fourteen participants had strabismus only (7 with esotropia, 6 with exotropia, and 1 with hypertropia).</description>
        </group>
        <group group_id="P4">
          <title>Ocular Comorbidities</title>
          <description>Four participants had ocular comorbidities: two with bilateral POAG and AMD; one had unilateral POAG and a symptomatic epiretinal membrane in the fellow eye; and one had bilateral POAG and congenital convergent strabismus.</description>
        </group>
        <group group_id="P5">
          <title>Healthy Volunteers</title>
          <description>Fifteen healthy volunteers with no self-reported history of ocular disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Retinal Disease</title>
          <description>Fourteen participants had bilateral retinal disease only (including 8 with age-related macular degeneration [AMD], 4 with diabetic macular edema, 1 with central serous retinopathy, and 1 with retinal vein occlusion with cystoid macular edema).</description>
        </group>
        <group group_id="B2">
          <title>Glaucoma</title>
          <description>Thirteen participants had glaucoma only (12 with primary open angle glaucoma [POAG], 1 with glaucoma secondary to hypertensive uveitis).</description>
        </group>
        <group group_id="B3">
          <title>Strabismus</title>
          <description>Fourteen participants had strabismus only (7 with esotropia, 6 with exotropia, and 1 with hypertropia).</description>
        </group>
        <group group_id="B4">
          <title>Ocular Comorbidities</title>
          <description>Four participants had ocular comorbidities: two with bilateral POAG and AMD; one had unilateral POAG and a symptomatic epiretinal membrane in the fellow eye; and one had bilateral POAG and congenital convergent strabismus.</description>
        </group>
        <group group_id="B5">
          <title>Healthy Volunteers</title>
          <description>Fifteen healthy volunteers with no self-reported history of ocular disease.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="14"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="15"/>
            <count group_id="B6" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.0" spread="11.4"/>
                    <measurement group_id="B2" value="64.1" spread="14.7"/>
                    <measurement group_id="B3" value="50.8" spread="19.1"/>
                    <measurement group_id="B4" value="70.5" spread="8.0"/>
                    <measurement group_id="B5" value="53.1" spread="11.2"/>
                    <measurement group_id="B6" value="60.3" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual acuity (better eye)</title>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.35" spread="0.24"/>
                    <measurement group_id="B2" value="0.10" spread="0.12"/>
                    <measurement group_id="B3" value="-0.04" spread="0.08"/>
                    <measurement group_id="B4" value="0.24" spread="0.42"/>
                    <measurement group_id="B5" value="0.01" spread="0.14"/>
                    <measurement group_id="B6" value="0.18" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual acuity (worse eye)</title>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="13"/>
                    <count group_id="B3" value="14"/>
                    <count group_id="B4" value="4"/>
                    <count group_id="B5" value="15"/>
                    <count group_id="B6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.68" spread="0.34"/>
                    <measurement group_id="B2" value="0.20" spread="0.12"/>
                    <measurement group_id="B3" value="0.24" spread="0.27"/>
                    <measurement group_id="B4" value="0.63" spread="0.53"/>
                    <measurement group_id="B5" value="0.02" spread="0.15"/>
                    <measurement group_id="B6" value="0.33" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Examination Time</title>
        <description>Total time for each participant to complete the binocular optical coherence tomography (OCT) examination was calculated.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Retinal Disease</title>
            <description>Fourteen participants had bilateral retinal disease only (including 8 with age-related macular degeneration [AMD], 4 with diabetic macular edema, 1 with central serous retinopathy, and 1 with retinal vein occlusion with cystoid macular edema).</description>
          </group>
          <group group_id="O2">
            <title>Glaucoma</title>
            <description>Thirteen participants had glaucoma only (12 with primary open angle glaucoma [POAG], 1 with glaucoma secondary to hypertensive uveitis).</description>
          </group>
          <group group_id="O3">
            <title>Strabismus</title>
            <description>Fourteen participants had strabismus only (7 with esotropia, 6 with exotropia, and 1 with hypertropia).</description>
          </group>
          <group group_id="O4">
            <title>Ocular Comorbidities</title>
            <description>Four participants had ocular comorbidities: two with bilateral POAG and AMD; one had unilateral POAG and a symptomatic epiretinal membrane in the fellow eye; and one had bilateral POAG and congenital convergent strabismus.</description>
          </group>
          <group group_id="O5">
            <title>Healthy Volunteers</title>
            <description>Fifteen healthy volunteers with no self-reported history of ocular disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Examination Time</title>
          <description>Total time for each participant to complete the binocular optical coherence tomography (OCT) examination was calculated.</description>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="728.6" lower_limit="654.7" upper_limit="826.4"/>
                    <measurement group_id="O2" value="676.7" lower_limit="626.4" upper_limit="747.7"/>
                    <measurement group_id="O3" value="707.6" lower_limit="636.9" upper_limit="847.9"/>
                    <measurement group_id="O4" value="620.6" lower_limit="598.1" upper_limit="753.7"/>
                    <measurement group_id="O5" value="637.8" lower_limit="572.4" upper_limit="821.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Subjective Ratings â‰¥ 4 on Post-Test Questionnaire</title>
        <description>Participants rated ease of use, duration, and appeal on a 5-point Likert scale in a post-test questionnaire.</description>
        <time_frame>6 months</time_frame>
        <population>Results based on a post-test questionnaire. Participants rated ease of use (from 1 to 5: 1 = very difficult, 5 = very easy), duration (from 1 to 5: 1 = very long, 5 = very short), and appeal (from 1 to 5: 1 = very unappealing, 5 = very appealing) on a 5-point Likert scale.</population>
        <group_list>
          <group group_id="O1">
            <title>Retinal Disease</title>
            <description>Fourteen participants had bilateral retinal disease only (including 8 with age-related macular degeneration [AMD], 4 with diabetic macular edema, 1 with central serous retinopathy, and 1 with retinal vein occlusion with cystoid macular edema).</description>
          </group>
          <group group_id="O2">
            <title>Glaucoma</title>
            <description>Thirteen participants had glaucoma only (12 with primary open angle glaucoma [POAG], 1 with glaucoma secondary to hypertensive uveitis).</description>
          </group>
          <group group_id="O3">
            <title>Strabismus</title>
            <description>Fourteen participants had strabismus only (7 with esotropia, 6 with exotropia, and 1 with hypertropia).</description>
          </group>
          <group group_id="O4">
            <title>Ocular Comorbidities</title>
            <description>Four participants had ocular comorbidities: two with bilateral POAG and AMD; one had unilateral POAG and a symptomatic epiretinal membrane in the fellow eye; and one had bilateral POAG and congenital convergent strabismus.</description>
          </group>
          <group group_id="O5">
            <title>Healthy Volunteers</title>
            <description>Fifteen healthy volunteers with no self-reported history of ocular disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Subjective Ratings â‰¥ 4 on Post-Test Questionnaire</title>
          <description>Participants rated ease of use, duration, and appeal on a 5-point Likert scale in a post-test questionnaire.</description>
          <population>Results based on a post-test questionnaire. Participants rated ease of use (from 1 to 5: 1 = very difficult, 5 = very easy), duration (from 1 to 5: 1 = very long, 5 = very short), and appeal (from 1 to 5: 1 = very unappealing, 5 = very appealing) on a 5-point Likert scale.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rated â‰¥ 4 ease of use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rated â‰¥ 4 duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rated â‰¥ 4 appeal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Presented Gradable Data, by Examination Type</title>
        <description>To identify potential user errors, particularly those with a likelihood of generating erroneous examination findings (e.g., failure to comply with device instructions or errors in voice recognition).</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Retinal Disease</title>
            <description>Fourteen participants had bilateral retinal disease only (including 8 with age-related macular degeneration [AMD], 4 with diabetic macular edema, 1 with central serous retinopathy, and 1 with retinal vein occlusion with cystoid macular edema).</description>
          </group>
          <group group_id="O2">
            <title>Glaucoma</title>
            <description>Thirteen participants had glaucoma only (12 with primary open angle glaucoma [POAG], 1 with glaucoma secondary to hypertensive uveitis).</description>
          </group>
          <group group_id="O3">
            <title>Strabismus</title>
            <description>Fourteen participants had strabismus only (7 with esotropia, 6 with exotropia, and 1 with hypertropia).</description>
          </group>
          <group group_id="O4">
            <title>Ocular Comorbidities</title>
            <description>Four participants had ocular comorbidities: two with bilateral POAG and AMD; one had unilateral POAG and a symptomatic epiretinal membrane in the fellow eye; and one had bilateral POAG and congenital convergent strabismus.</description>
          </group>
          <group group_id="O5">
            <title>Healthy Volunteers</title>
            <description>Fifteen healthy volunteers with no self-reported history of ocular disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Presented Gradable Data, by Examination Type</title>
          <description>To identify potential user errors, particularly those with a likelihood of generating erroneous examination findings (e.g., failure to comply with device instructions or errors in voice recognition).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anterior segment imaging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior segment imaging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitreous imaging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual acuity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suprathreshold perimetry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pupillometry</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Retinal Disease</title>
          <description>Fourteen participants had bilateral retinal disease only (including 8 with age-related macular degeneration [AMD], 4 with diabetic macular edema, 1 with central serous retinopathy, and 1 with retinal vein occlusion with cystoid macular edema).</description>
        </group>
        <group group_id="E2">
          <title>Glaucoma</title>
          <description>Thirteen participants had glaucoma only (12 with primary open angle glaucoma [POAG], 1 with glaucoma secondary to hypertensive uveitis).</description>
        </group>
        <group group_id="E3">
          <title>Strabismus</title>
          <description>Fourteen participants had strabismus only (7 with esotropia, 6 with exotropia, and 1 with hypertropia).</description>
        </group>
        <group group_id="E4">
          <title>Ocular Comorbidities</title>
          <description>Four participants had ocular comorbidities: two with bilateral POAG and AMD; one had unilateral POAG and a symptomatic epiretinal membrane in the fellow eye; and one had bilateral POAG and congenital convergent strabismus.</description>
        </group>
        <group group_id="E5">
          <title>Healthy Volunteers</title>
          <description>Fifteen healthy volunteers with no self-reported history of ocular disease.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pearse Keane</name_or_title>
      <organization>Moorfields Eye Hospital NHS Foundation Trust</organization>
      <phone>02072533411</phone>
      <email>pearse.keane@moorfields.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

